• Korean Circulation Journal
• /
• 제53권6호
• /
• pp.406-417
• /
• 2023

Background and Objectives: Pathophysiological changes of right ventricle (RV) after repair of tetralogy of Fallot (TOF) are coupled with a highly compliant low-pressure pulmonary artery (PA) system. This study aimed to determine whether pulmonary vascular function was associated with RV parameters and exercise capacity, and its impact on RV remodeling after pulmonary valve replacement. Methods: In a total of 48 patients over 18 years of age with repaired TOF, pulmonary arterial elastance (Ea), RV volume data, and RV-PA coupling ratio were calculated and analyzed in relation to exercise capacity. Results: Patients with a low Ea showed a more severe pulmonary regurgitation volume index, greater RV end-diastolic volume index, and greater effective RV stroke volume (p=0.039, p=0.013, and p=0.011, respectively). Patients with a high Ea had lower exercise capacity than those with a low Ea (peak oxygen consumption [peak VO₂] rate: 25.8±7.7 vs. 34.3±5.5 mL/kg/min, respectively, p=0.003), while peak VO₂ was inversely correlated with Ea and mean PA pressure (p=0.004 and p=0.004, respectively). In the univariate analysis, a higher preoperative RV end-diastolic volume index and RV end-systolic volume index, left ventricular end-systolic volume index, and higher RV-PA coupling ratio were risk factors for suboptimal outcomes. Preoperative RV volume and RV-PA coupling ratio reflecting the adaptive PA system response are important factors in optimal postoperative results. Conclusions: We found that PA vascular dysfunction, presenting as elevated Ea in TOF, may contribute to exercise intolerance. However, Ea was inversely correlated with pulmonary regurgitation (PR) severity, which may prevent PR, RV dilatation, and left ventricular dilatation in the absence of significant pulmonary stenosis.

• Journal of Chest Surgery
• /
• 제35권9호
• /
• pp.664-667
• /
• 2002

선천성 심질환에 대한 개심술후 발생한 폐동맥 고혈압 위기증이 혈관확장제 등의 내과적 치료에 반응하지 않는 경우에 체외막 산소화 장치를 사용함으로써, 안정적인 산소공급의 확보를 통한 폐혈관 저항의 상승 방지, 심박출량의 상당 부분의 바이패스를 통한 폐관류압의 감소, 우심실의 용적 부하 감소 및 심실보조 기능을 통한 우심부전 및 저심박출의 예방 등의 치료 효과를 기대할 수 있다. 본 증례의 경우, 동맥관 개존증과 이차성 폐동맥 고혈압이 합병되어 있었던 37세 남자에서 수술후 발생한 폐동맥 고혈압 위기증에 대한 치료시 체외막 산소화 장치를 함께 사용하여 좋은 결과를 얻었기에 보고하는 바이다.

• Journal of Chest Surgery
• /
• 제33권3호
• /
• pp.221-229
• /
• 2000

Background: Thromboxane A2 and endothelin-1 are the potent vasoconstrictors affecting pulmonary pathophysiology in response to whole body inflammatin following CPB. Aprotinin, as an antiiflammatory agent, may decrease the release of such vasoactive substance from pulmonary tissues, preventing pulmonary hypertension after cardiopulmonary bypass. Material and Method: Ten mongrel dogs(Bwt. ac. 20kg) were subjected to cardioupulmonary bypass for 2 hours and postbypass pulmonary vascular resistance(0, 1, 2, 3 hours) were compared with prebypass level. The dogs were divided into 2 groups; control group(n-5) and aprotinin group(n=5). In the aprotinin group, aprotinin was administered as follows; 50,000 KIU/kg mixed in pump priming solution, 50,000 KIU/kg prebypass intravenous infusion over 30 minutes, 10,000 KIU/kg/hour postbypass continuous infusion. Prebypass and postbypass 0, 1, 2, 3 hour pulmonary vascular resistance were measured. At prebypass and postbypass 0, 90, 180 minutes, blood samples were obtained from pulmonary arterial and left atrial catherers for the assay of plasma thromboxane B2 a stable metabolite of thromboxane A2, and endothelin-1 concentrations. Result: The ratios of pustbypass over prebypass pulmonary vascular at postbypass 0, 1, 2, 3 hours were 1.28$\pm$0.20, 1.82$\pm$0.23, 1.90$\pm$0.19, 2.14$\pm$0.18 in control group, 1.58$\pm$0.18, 1.73$\pm$0.01, 1.66$\pm$0.10, 1.50$\pm$0.08 in aprotinin group ; the ratios gradually increased in control group while decreased or fluctuated after postbypass 1 hour in aprotinin group. There was statistically significant difference between control group and aprotinin group at postbypass 3 hours(P=0.014). Pulmonary arterial plasma concentration of thromboxane B2(pg/ml) at prebypass, postbypass 0, 90, 180 minutes were 346.4$\pm$61.9, 529.3$\pm$197.6, 578.3$\pm$255.8, 493.3$\pm$171.3 in control group, 323.8$\pm$118.0, 422.6$\pm$75.6, 412.3$\pm$59.9, 394.5$\pm$154.0 in aprotinin group. Left atrial concentrations were 339.3$\pm$89.2, 667.0$\pm$65.7, 731.2$\pm$192.7, 607.5$\pm$165.9 in control group, 330.0$\pm$111.2, 468.4$\pm$190.3, 425.4$\pm$193.6, 4.7.3$\pm$142.8 in aprotinin group. These results showed decrement of pulmonary thromboxane A2 generation in aprotinin group. Pulmonary arterial concentrations of endothelin-1(fmol/ml) at the same time sequence were 7.84$\pm$0.31, 13.2$\pm$0.51, 15.0$\pm$1.22, 16.3$\pm$1.73 in control group, 7.76$\pm$0.12, 15.3$\pm$0.71, 22.6$\pm$6.62, 14.9$\pm$1.11 in aprotinin group. Left atrial concentrations were 7.61$\pm$17.2, 57.1$\pm$28.4, 18.9$\pm$18.2, 31.5$\pm$20.5 in control group, 5.61$\pm$7.61, 37.0$\pm$26.2, 28.6$\pm$21.7, 37.8$\pm$30.6 in aprotinin group. These results showed that aprotinin had no effect on plasma endothelin-1 concentration after cardiopulmonary bypass. Conclusion: Administration of aprotinin during cardiopulmonary bypass could attenuate the increase in pulmonary vascular resistance after bypass. Inhibition of pulmonary thromboxane A2 generation was thought to be one of the mechanism of this effect. Aprotinin had no effect on postbypass endothelin-1 concentration.

• Journal of Chest Surgery
• /
• 제23권1호
• /
• pp.32-40
• /
• 1990

Surgical correction of congenital cardiac defects in infants and children with an elevated pulmonary arterial pressure or pulmonary vascular resistance carries a significant early postoperative mortality. And accurate assessments of cardiac output is critically important in these patients. From April 1988 through September 1989, serial measurements of cardiac index, ratio of pulmonary-systemic systolic pressure, ratio of pulmonary-systemic resistance, central venous pressure, left atrial pressure, and urine output during the first 48 hours after the cardiac operation were made in 30 congenital cardiac defects associated with pulmonary hypertension. Cardiac index showed significant increase only after 24 hour postoperatively and this low cardiac performance in the early postoperative period should be considered when postoperative management is being planned in the risky patients. There were no variables which showed any significant correlation with cardiac index. In 12 cases[40%], pulmonary hypertensive crisis developed during the 48 hours postoperatively, and they were treated with full sedation, hyperventilation with 100 % 0y and pulmonary vasodilator infusion. In all patient with preoperative pulmonary hypertension, surgical placement of a pulmonary artery catheter is desirable to allow prompt diagnosis of pulmonary hypertensive crisis and to monitor subsequent therapy.

• The Korean Journal of Physiology and Pharmacology
• /
• 제20권5호
• /
• pp.441-447
• /
• 2016

Despite the complex vascular effects of dexmedetomidine (DEX), its actions on human pulmonary resistance arteries remain unknown. The present study tested the hypothesis that DEX inhibits vascular tension in human pulmonary arteries through the endothelial nitric oxide synthase (eNOS) mediated production of nitric oxide (NO). Pulmonary artery segments were obtained from 62 patients who underwent lung resection. The direct effects of DEX on human pulmonary artery tension and changes in vascular tension were determined by isometric force measurements recorded on a myograph. Arterial contractions caused by increasing concentrations of serotonin with DEX in the presence or absence of L-NAME (endothelial nitric oxide synthase inhibitor), yohimbine (${\alpha}_2$-adrenoceptor antagonist) and indomethacin (cyclooxygenase inhibitor) as antagonists were also measured. DEX had no effect on endothelium-intact pulmonary arteries, whereas at concentrations of $10^{-8}{\sim}10^{-6}mol/L$, it elicited contractions in endothelium-denuded pulmonary arteries. DEX (0.3, 1, or $3{\times}10^{-9}mmol/L$) inhibited serotonin-induced contraction in arteries with intact endothelium in a dose-dependent manner. L-NAME and yohimbine abolished DEX-induced inhibition, whereas indomethacin had no effect. No inhibitory effect was observed in endothelium-denuded pulmonary arteries. DEX-induced inhibition of vasoconstriction in human pulmonary arteries is mediated by NO production induced by the activation of endothelial ${\alpha}_2$-adrenoceptor and nitric oxide synthase.

• Journal of Chest Surgery
• /
• 제21권5호
• /
• pp.911-917
• /
• 1988

Pulmonary thromboembolism originated most commonly from the venous thrombus, especially deep vein thrombus in the leg, which migrated to and occluded the pulmonary vasculatures. The failure of clot lysis and repeated embolic episodes resulted in the hemodynamic compromise -that is- in the increasing in the pulmonary vascular resistance, which would cause the right ventricle failure[Car Pulmonale]. Under the cardiopulmonary bypass, 20 year old male patient was treated successfully by thromboembolectomy of pulmonary thromboembolism with pulmonary hypertension, which originated from the deep vein thrombus in the leg. The results of radiologic studies and clinical evaluations were excellent in that the postoperative lung perfusion scan showed the newly increased perfusion of post-embolectomy territories and in the arterial blood gas finding of 76 from 66[mmHg] in PaO2. The patient was uneventful and discharged on postop. $ 14 days with anticoagulant continued.

• Journal of Chest Surgery
• /
• 제17권2호
• /
• pp.250-256
• /
• 1984

Eisenmenger syndrome is a condition which systemic arterial blood oxygen unsaturation occurs if obstruction in the pulmonary capillaries raises the pulmonary vascular resistance and pulmonary arterial pressure to or beyond systemic levels and then a significant right to left shunt develops across a preexisting cardiac septal defect or an aortopulmonary communication-We have experienced 3 cases of similar condition. Case I is 24 year old man who has had cyanosis and dyspnea on exertion since childhood. His pulmonary arterial pressure was 110/80mmHg. He was operated under diagnosis of the mitral stenosis and tetralogy of Fallot, but it was finally discovered that he had patent ductus arteriosus and ventricular defect was closed with perforated prosthetic patch, but the patient expired due to right heart failure low cardiac output. Case II was 16 year old female who had pulmonary hypertension of 110/85mmHg. She was diagnosed as Eisenmenger syndrome combining with atrial septal defect and patent ductus arteriosus. Case III was 20 year old male. His pulmonary arterial pressure was 110/70mmHg and the underlying defect was patent ductus arteriosus.

• Tuberculosis and Respiratory Diseases
• /
• 제60권2호
• /
• pp.142-150
• /
• 2006

Pulmonary arterial hypertension (PAH) is often difficult to diagnose and challenging to treat. Untreated, it is characterized by a progressive increase in pulmonary vascular resistance leading to right ventricular failure and death. The past decade has seen remarkable improvements in therapy, driven largely by the conduct of randomized controlled trials. Still, the selection of most appropriate therapy is complex, and requires familiarity with the disease process, evidence from treatment trials, complicated drug delivery systems, dosing regimens, side effects, and complications. We tried to provide evidence-based treatment recommendations for physicians involved in the care of these complex patients. Due to the complexity of the diagnostic evaluation required, and the treatment options available, it is strongly recommended that consideration be given to referral of patients with PAH to a specialized center.

• Tuberculosis and Respiratory Diseases
• /
• 제40권2호
• /
• pp.135-146
• /
• 1993

연구배경 : 급성 폐동맥색전증에서의 심폐기능 장애는 폐혈관계의 물리적 폐쇄와 신경체액성 반응에 의한 이차적인 기관지 및 혈관의 수축에 의하며, 혈소판에서 유리되는 serotonin이 체액성반응의 주 매개체인 것으로 알려져 있다. Positive End Expiratory Pressure(이하 PEEP 이라 칭함) 호흡요법은 성인성 호흡곤란증후군에서는 그 효과가 입증되어 널리 이용되고 있으나 폐동맥색전증에서의 역할은 아직 알려진 바 없다. 방법 : 연구자는 5-hydroxytryptamine 2 (이하 5-HT2라 칭함) 수용체의 선별 길항제인 ketanserin과 PEEP이 폐동맥색전증의 심폐기능 장애에 미치는 영향을 관찰하고 이들이 폐동맥색전증의 치료에 이용될 수 있을지를 검정해보기위해 한국산 잡견 13마리에 자가혈병을 이용하여 급성 폐동맥색전증을 일으킨후 대조군과 ketanserin 투여군, PEEP 적용군에서 환기 및 혈류역학의 제지표를 측정하여 다음과 같은 결과를 얻었다. 결과: 1) 폐동맥색전증을 일으키는데 사용된 혈병은 체중 Kg당 0.30~0.89($0.63{\pm}0.16$)gm 이었고 세 군간에 유의한 차이가 없었으며 평균 폐동맥압은 11~18($14{\pm}2$)mmHg 에서 색전증 유발 직후 38~46($42{\pm}2$)mmHg 까지 상승하였다. 2) 혈병 투여 30분후의 변화 혈병 투여 30분후 평균 폐동맥압 및 폐혈관저항은 증가하였고 심박출량은 감소하였으며, 동맥혈 산소분압과 산소운반량 및 혼합정맥혈 산소분압은 감소하였고 생리적 단락과 동맥혈 이산화탄소분압은 증가하였으며(p<0.05) 세 군간에 유의한 차이는 없었다. 대조군은 이후 실험기간중 상기 지표에 유의한 변화가 없었다. 3) Ketanserin 투여후의 변화 Ketanserin 투여후 대조군에 비해 평균 폐동맥압과 폐혈관저항은 낮았으며 심박출량은 높았고 생리적단락은 낮았으며 동맥혈 산소분압과 산소운반량은 높았다(p<0.05). 동맥혈 이산화탄소분압은 ketanserin 투여 30분후 감소하였다(p<0.05). 평균 전신동맥압은 ketanserin 122mmHg 에서 101mmHg로 하강하였고 한시간 후에는 투여전 수준으로 상승하였으며 통계적 유의성은 없었다. 혼합정맥혈 산소분압은 대조군에 비해 높은 경향을 보였으며 통계적 유의성은 없었다. 4) PEEP 적용군에서의 변화 PEEP 적용후 동맥혈 산소분압과 폐혈관저항은 증가하였고 심박출량은 감소하였으며 생리적 단락은 감소한 반면 산소운반량은 감소하였다(p<0.05). 한편 동맥혈 이산화탄소분압은 증가하였다(p<0.05). PEEP 제거후 평균 폐동맥압과 폐혈관저항은 감소해 대조군에 비해 낮았으며, 산소운반량과 심박출량은 증가해 대조군에 비해 높았다(p<0.05). 생리적단락은 대조군에 비해 낮았고(p<0.05) 동맥혈 이산화탄소분압은 감소해 대조군과 유의한 차이는 없었다. 혼합정맥혈 산소분압은 대조군에 비해 높았다(p<0.05). 5) 혈병 투여 4시간후 혈소판은 감소하였고 백혈구는 증가하였다(p<0.05). 결론 : 이상의 결과로 5-HT2 수용체의 선별 길항제인 ketanserin은 폐동맥색전증의 치료에 유용할 것으로 생각된다. 한편 PEEP용 적용증에는 혈류역학적 제지표가 악화되었으나 제거후에는 오히려 대조군에 비해 유의하게 호전되었으므로, 폐동맥색전증의 초기에 혈류역학적 상태가 허용되면 조심스럽게 단기간 적용해볼 수 있을 것으로 생각된다.

• Journal of Chest Surgery
• /
• 제39권8호
• /
• pp.579-587
• /
• 2006

배경 : 단심실 교정을 시행함에 있어 수술 전 위험 인자가 많지 않다고 판단되는 경우에도 수술 후 장기간의 흉관 배액, 단백 소모성 장질환, 폐혈관 색전증, 사망 등의 불량한 결과를 얻을 수 있다. 이러한 측면에서, 단심실 교정에 대한 기존의 위험 인자 분석은 수술 결과를 예측함에 있어 미흡한 점이 있다고 할 수 있다. 저자 등은 폐혈관 유순도를 새로이 정의하고, 낮은 폐혈관 유순도가 수술 후 흉관 배액 기간을 길게 한다는 가설을 세워 이를 증명하고자 하였다. 대상 및 방법 : 2002년 1월부터 2005년 5월까지 심장 외 도관을 이용한 단심실 교정을 받은 총 96 명의 환자들의 기록을 후행적으로 분석하였다. 동 기간 중 기존의 단심실 교정을 심장 외 도관으로 교체한 경우는 연구 대상에서 제외하였다. 수술 후 늑막 삼출 기간의 위험 인자 분석에는 12가지 수술 전 위험 인자들을 지수화한 Fontan risk score (FRS) 및 기타 다양한 수술 전, 수술 중 위험 인자들을 포함시켰으며, 본 연구를 위하여 전기로 analogue를 폐순환에 적용하여 계산된 폐혈관 유순도 (pulmonary vascular compliance, PVC, $mm^2/mmHg/m^2)$를 위험인자로 추가하였다. 전기 회로 analogue에 의하면 PVC는 폐동맥 지수 (pulmonary artery index, $mm^2/m^2$)를 총폐저항 (total pulmonary resistance, Wood $Unit{\cdot}m^2$) 및 폐 혈류량 (pulmonary blood flow, $L/min/m^2$) 으로 나눈 값으로 정의되며, 이는 폐혈관의 크기와 저항, 폐 혈류량 등을 동시에 고려하는 변수라고 할 수 있다. 결과 변수인 흉관 거치 기간은 자연로그를 취해 정규 분포화하고 이를 log indwelling time (LIT)으로 정의하였으며, 분석 대상 위험 인자들과 LIT 의 관계에 대한 다중 선형 회귀분석을 시행하였다. 결과 : 조기 사망은 없었고 만기 사망은 4 명 (4.2%)이었으며, 단심실 교정시 fenestration이 추가된 경우는 1예 있었다(1 %). 수술 전 PVC, 흉관 거치 기간, LIT는 각각 ${6{\sim}94.8\;mm^2/mmHg/m^2}$ (중간값:24.8), $3{\sim}268$일 ( 간값 : 20 일 ), $1.1{\sim}5.6$ ( 평균: 2.9, 표준 편차: 0.8) 이었다. 단변 수 분석상 FRS, PVC, 체외 순환시간 (CPB) 및 술 후 12 시간째의 중심 정맥압 등이 LIT와 연관되었으나, 다변수 분석상 PVC (p=0.0018) 및 CPB (p=0.0024)만이 독립적으로 LIT를 예측하였다. 두 변수는 LIT 변이에 대하여 21.7%의 설명력이 있었으며, 두 변수를 이용한 회귀 분석식은 다음과 같았다. LIT=2.74-0.0158 PVC+0.00658 CPB. 결론: 새로이 정의된 폐혈관 유순도는 심장 외 도관을 이용한 단심실 교정 후의 흉관 거치 기간을 결정하는 중요한 예측 인자로서, 수술 전 위험 인자 분석에 유용하게 사용될 수 있다.